Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) FCF Margin (2024 - 2025)

Historic FCF Margin for Neuphoria Therapeutics (NEUP) over the last 2 years, with Q2 2025 value amounting to 27135.0%.

  • Neuphoria Therapeutics' FCF Margin changed N/A to 27135.0% in Q2 2025 from the same period last year, while for Dec 2025 it was 15.61%, marking a year-over-year increase of 11600300.0%. This contributed to the annual value of 0.64% for FY2025, which is N/A changed from last year.
  • As of Q2 2025, Neuphoria Therapeutics' FCF Margin stood at 27135.0%.
  • Neuphoria Therapeutics' 5-year FCF Margin high stood at 27135.0% for Q2 2025, and its period low was 506.72% during Q4 2024.